

Tumor Blood Testing Market Insights Highlight Segment Expansion And Market Leadership

The Business Research Company's Tumor Blood Testing Market Insights Highlight Segment Expansion And Market Leadership

LONDON, GREATER LONDON, UNITED KINGDOM, September 1, 2026

/EINPresswire.com/ -- "The [tumor blood testing market](#) has been

expanding swiftly, fueled by advancements in cancer diagnostics and an increasing need for less invasive testing options. As technology progresses and cancer prevalence rises globally, this market is set to experience significant growth in the coming years. Below, we explore the current market size, key growth drivers, regional trends, and the innovative developments shaping this sector.

“

Expected to grow to \$11.13 billion in 2030 at a compound annual growth rate (CAGR) of 13.2%”

The Business Research Company

Market Size and Growth Outlook for Tumor Blood Testing

The tumor blood testing market has witnessed rapid expansion recently, with its value projected to rise from \$5.98 billion in 2025 to \$6.78 billion in 2026, reflecting a strong compound annual growth rate (CAGR) of 13.3%. This increase can be linked to factors such as the growing

incidence of cancer, limitations associated with traditional tissue biopsies, advances in genomic testing technologies, increased funding for oncology research, and a rising preference for non-invasive diagnostic tools. Looking ahead, the market is expected to continue its upward trajectory, reaching \$11.13 billion by 2030, driven by a CAGR of 13.2%. The forecast period's growth will likely benefit from initiatives such as early cancer screening programs, AI-powered genomic analyses, the expansion of personalized medicine, broader adoption of companion diagnostics, and the incorporation of tumor blood testing in clinical trials. Key trends anticipated to influence the market include wider use of liquid biopsy, multi-cancer early detection techniques, monitoring of minimal residual disease, personalized oncology testing, and enhanced sensitivity in biomarker detection.

Download a free sample of the [tumor blood testing market report](#):

The Business
Research Company

The Business Research Company



https://www.thebusinessresearchcompany.com/sample.aspx?id=28343&type=smp&utm_source=EINPresswire&utm_medium=Paid&utm_campaign=Sep_PR

Understanding Tumor Blood Testing as a Technique

Tumor blood testing is an innovative diagnostic method involving the analysis of blood samples to detect cancer-specific biomarkers. It primarily focuses on identifying genetic materials released by tumors, such as circulating tumor DNA (ctDNA), offering a less invasive alternative to conventional tissue biopsies. This approach facilitates earlier cancer diagnosis, continuous monitoring of disease progression, and improved decision-making regarding treatment plans, making it a valuable tool in oncology care.

Key Factors Driving Growth in the Tumor Blood Testing Market

One of the primary forces propelling the tumor blood testing market is the rising incidence of cancer worldwide. Factors such as aging populations, unhealthy lifestyle choices including poor diet and smoking, as well as environmental pollution, are contributing to an increase in cancer cases. These developments have intensified demand for early detection methods that are minimally invasive. Tumor blood testing meets this need by detecting cancer biomarkers in the bloodstream before symptoms emerge, enabling timely diagnosis, early intervention, better patient outcomes, and ongoing monitoring of treatment efficacy. For instance, in May 2024, the National Cancer Institute—a US government agency—reported that as of January 2022, the United States had approximately 18.1 million cancer survivors, with projections estimating this figure to reach 26 million by 2040. This growing cancer survivor population underscores the expanding relevance and demand for tumor blood testing.

View the full tumor blood testing market report:

https://www.thebusinessresearchcompany.com/report/tumor-blood-testing-global-market-report?utm_source=EINPresswire&utm_medium=Paid&utm_campaign=Sep_PR

Regional Developments and Growth Patterns in Tumor Blood Testing

In terms of geography, North America accounted for the largest share of the tumor blood testing market in 2025. However, Asia-Pacific is projected to be the fastest-growing region throughout the forecast period. The comprehensive market analysis includes important regions such as Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, the Middle East, and Africa, providing a global perspective on growth opportunities and challenges within the tumor blood testing sector.

The 2026 edition of our market reports now delivers enhanced analytical coverage through market attractiveness scoring and analysis, total addressable market (TAM) analysis, company scoring matrix graphics and tables, Excel-based forecasting dashboards, market hotspots infographics, key technologies and future trend analysis, plus updated graphics and tables.

Speak With Our Expert:
Saumya Sahay

Americas +1 310-496-7795
Asia +44 7882 955267 & +91 8897263534
Europe +44 7882 955267
Email: marketing@tbrc.info

The Business Research Company - www.thebusinessresearchcompany.com

Follow Us On:

• LinkedIn: <https://in.linkedin.com/company/the-business-research-company>"

Oliver Guirdham
The Business Research Company
+44 7882 955267
info@tbrc.info

Visit us on social media:

[LinkedIn](#)

[Facebook](#)

[X](#)

This press release can be viewed online at: <https://www.einpresswire.com/article/938697642>

EIN Presswire's priority is source transparency. We do not allow opaque clients, and our editors try to be careful about weeding out false and misleading content. As a user, if you see something we have missed, please do bring it to our attention. Your help is welcome. EIN Presswire, Everyone's Internet News Presswire™, tries to define some of the boundaries that are reasonable in today's world. Please see our Editorial Guidelines for more information.

© 1995-2026 Newsmatics Inc. All Right Reserved.